West Pharmaceutical Services (WPS) Stock Price & Analysis
WPS Stock Chart & Stats
- Day’s Range
- EUR 374.30 - EUR 380.40
- 52-Week Range
- EUR 191.35 - EUR 380.80
- Previous Close
- EUR 355.70
- Volume
- 0
- Average Volume (3M)
- 5
- Market Cap
- EUR 25.65B
- Enterprise Value
- EUR 26.10B
- Total Cash (Recent Filing)
- EUR 464.10M
- Total Debt (Recent Filing)
- EUR 305.00M
- Price to Earnings (P/E)
- 46.0
- Beta
- 0.26
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 2.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.20%
Bulls Say, Bears Say
Bulls Say
High-Value Product Leadership
High-value components are central to West’s revenue base and benefit from biologics, GLP-1 therapies, and qualified customer applications. Their critical role in injectable containment can support repeat demand, stronger product mix, and durable competitive positioning over the next several quarters.
Raised Growth And Margin Outlook
Management’s higher revenue outlook and planned margin expansion indicate strong underlying demand and operating execution rather than reliance solely on temporary volume. Improved mix, pricing, plant performance, and leverage can strengthen earnings power and support reinvestment in growth.
Conservative Balance Sheet And Cash Generation
Low leverage gives West meaningful financial flexibility across industry cycles and reduces pressure from interest obligations. Healthy operating and free cash flow provide internal funding for capacity expansion, customer support, dividends, and other strategic priorities without depending heavily on additional debt.
Bears Say
West Vantage Portfolio Transition
The West Vantage decline shows that portfolio transition is currently offsetting gains from new, higher-value drug-handling programs. Muted growth expected this year and next could weigh on consolidated momentum while replacement projects ramp and legacy revenue continues to roll off.
Uneven Cash Conversion
Working-capital investment is absorbing more cash even as operations expand, reducing near-term cash conversion and limiting the portion of earnings available for discretionary uses. If receivables and inventory remain elevated, funding capacity for buybacks, dividends, or expansion could be less efficient.
Delivery Device And SmartDose Headwinds
The delivery-device business has uneven quarterly performance, and the SmartDose 3.5 divestiture removes an existing revenue stream. These factors can make reported growth less consistent and require new product adoption and customer programs to offset the resulting portfolio headwind.
West Pharmaceutical Services News
WPS FAQ
What was West Pharmaceutical Services’s price range in the past 12 months?
What is West Pharmaceutical Services’s market cap?
When is West Pharmaceutical Services’s upcoming earnings report date?
How were West Pharmaceutical Services’s earnings last quarter?
Is West Pharmaceutical Services overvalued?
Does West Pharmaceutical Services pay dividends?
What is West Pharmaceutical Services’s EPS estimate?
How many shares outstanding does West Pharmaceutical Services have?
What happened to West Pharmaceutical Services’s price movement after its last earnings report?
Which hedge fund is a major shareholder of West Pharmaceutical Services?
What is the TipRanks Smart Score and how is it calculated?
West Pharmaceutical Services Stock Smart Score
Company Description
West Pharmaceutical Services
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Michel Lagarde
- Employees
- 10,800
- Website
- www.westpharma.com
- Address
- 530 Herman O. West Drive, Exton, PA, 19341-1147, US
West Pharmaceutical Services (WPS) Earnings & Revenues
WPS Company Deck
WPS Earnings Call
Earnings Call SentimentPositive
The call was strongly positive: West exceeded Q3 revenue and earnings expectations, delivered broad-based organic growth, expanded margins significantly, raised full-year revenue and EPS guidance, and reported strong demand across HVP Components, GLP-1, biologics, and multiple geographies. The main challenges were the West Vantage decline, SmartDose 3.5 divestiture-related revenue effects, a 5% year-to-date free-cash-flow decrease, and expected moderation in HVP Delivery Device growth in Q4.
View all DE:WPS earnings summariesWPS Net sales Breakdown
- 81.07% Proprietary Products
- 18.93% Contract-Manufactured Products
- 0.00% Intersegment sales elimination
WPS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |